Hennion & Walsh Asset Management Inc. Acquires 113,539 Shares of Grifols, S.A. $GRFS

Hennion & Walsh Asset Management Inc. grew its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 31.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 478,769 shares of the biotechnology company’s stock after purchasing an additional 113,539 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Grifols were worth $4,476,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brandes Investment Partners LP boosted its holdings in Grifols by 8.9% in the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after acquiring an additional 2,294,113 shares in the last quarter. Capital World Investors increased its holdings in shares of Grifols by 5.9% during the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock valued at $228,344,000 after acquiring an additional 1,273,391 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Grifols by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock valued at $29,948,000 after acquiring an additional 80,507 shares in the last quarter. Bank of America Corp DE raised its position in shares of Grifols by 32.3% in the 3rd quarter. Bank of America Corp DE now owns 3,992,804 shares of the biotechnology company’s stock worth $39,768,000 after purchasing an additional 975,129 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Grifols by 3,205.1% in the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after purchasing an additional 2,922,540 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on GRFS shares. JPMorgan Chase & Co. cut their price objective on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Wall Street Zen upgraded shares of Grifols from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings cut shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $10.00.

Grifols Trading Up 0.9%

Shares of NASDAQ:GRFS opened at $7.56 on Tuesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.51 and a quick ratio of 0.88. Grifols, S.A. has a 1 year low of $6.19 and a 1 year high of $11.14. The company has a market cap of $5.15 billion, a P/E ratio of 39.79, a PEG ratio of 0.26 and a beta of 0.67. The stock’s fifty day moving average price is $8.76 and its 200-day moving average price is $9.05.

Grifols (NASDAQ:GRFS) last released its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. Grifols had a return on equity of 6.23% and a net margin of 6.65%.The company had revenue of $2.32 billion during the quarter. Sell-side analysts expect that Grifols, S.A. will post 0.81 earnings per share for the current year.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.